BRAF and melanoma: Similarly, treating WM164 with a BRAF inhibitor in the presence of recombinant TGFβ1 (200 pg/mL) improved colony formation of the melanoma cells, despite the BRAF inhibitor, indicating the role of TGFβ1 in drug resistance.